| Title: |
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial |
| Authors: |
Ray, KK; Leiter, LA; Mueller-Wieland, D; Cariou, B; Colhoun, HM; Henry, RR; Tinahones, FJ; Bujas-Bobanovic, M; Domenger, C; Letierce, A; Samuel, R; Del Prato, S |
| Source: |
1489 ; 1479 |
| Publisher Information: |
Wiley |
| Publication Year: |
2018 |
| Collection: |
Imperial College London: Spiral |
| Subject Terms: |
Science & Technology; Life Sciences & Biomedicine; Endocrinology & Metabolism; mixed dyslipidaemia; non-HDL cholesterol; PCSK9; type 2 diabetes; DENSITY-LIPOPROTEIN CHOLESTEROL; PCSK9 INHIBITOR EVOLOCUMAB; CARDIOVASCULAR EVENTS; GENETIC-VARIANTS; POOLED ANALYSIS; AMG 145; EFFICACY; SAFETY; RISK; METAANALYSIS; 1103 Clinical Sciences |
| Description: |
Materials and Methods The UC options (no additional lipid‐lowering therapy; fenofibrate; ezetimibe; omega‐3 fatty acid; nicotinic acid) were selected prior to stratified randomization to open‐label alirocumab 75 mg every 2 weeks (with increase to 150 mg every 2 weeks at week 12 if week 8 non‐HDL cholesterol concentration was ≥2.59 mmol/L [100 mg/dL]) or UC for 24 weeks. The primary efficacy endpoint was percentage change in non‐HDL cholesterol from baseline to week 24. Results The randomized population comprised 413 individuals (intention‐to‐treat population, n = 409; safety population, n = 412). At week 24, the mean non‐HDL cholesterol reductions were superior with alirocumab (−32.5% difference vs UC, 97.5% confidence interval −38.1 to −27.0; P < .0001). Overall, 63.6% of alirocumab‐treated individuals were maintained on 75 mg every 2 weeks. Alirocumab also reduced LDL cholesterol (−43.0%), apolipoprotein B (−32.3%), total cholesterol (−24.6%) and LDL particle number (−37.8%) at week 24 vs UC (all P < .0001). Consistent with the overall trial comparison, alirocumab reduced non‐HDL cholesterol to a greater degree within each UC stratum at week 24. The incidence of treatment‐emergent adverse events was 68.4% (alirocumab) and 66.4% (UC). No clinically meaningful effect on glycated haemoglobin, or change in number of glucose‐lowering agents, was seen. Conclusions In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non‐HDL cholesterol reduction and was generally well tolerated. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
Diabetes, Obesity and Metabolism; http://hdl.handle.net/10044/1/59821; https://dx.doi.org/10.1111/dom.13257 |
| DOI: |
10.1111/dom.13257 |
| Availability: |
http://hdl.handle.net/10044/1/59821; https://doi.org/10.1111/dom.13257 |
| Rights: |
© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. his is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribut ion in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Accession Number: |
edsbas.E75A8520 |
| Database: |
BASE |